Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Items 301–400 of 1,000
Targeting myeloid cells using nanoparticles to improve cancer immunotherapy
Amoozgar, Z., & Goldberg, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.007 · Cited by 73
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
Carpenter, E. L., Haglund, E. A., Mace, E. M., Deng, D., Martínez, D., Wood, A., Chow, A. K., Weiser, D. A., Belcastro, L. T., Winter, C. L., et al. (2012) · Oncogene · doi:10.1038/onc.2011.647 · Cited by 73
Self-citationNile, D. L., Rae, C. J., Hyndman, I., Gaze, M. N., & Mairs, R. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2656-8 · Cited by 73
“This could possibly be improved with immunotherapy, which has proven an effective treatment for high-risk neuroblastoma patients in remission [4], but further improvements are necessary to limit adverse cytotoxic effects.”
BackgroundSano, R., Krytska, K., Larmour, C., Raman, P., Martínez, D., Ligon, G. F., Lillquist, J. S., Cucchi, U., Orsini, P., Rizzi, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau9732 · Cited by 70
Second malignancies in patients with neuroblastoma: The effects of risk‐based therapy
Applebaum, M. A., Henderson, T. O., Lee, S. M., Pinto, N. R., Volchenboum, S. L., & Cohn, S. L. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25249 · Cited by 71
“3), similar to historic controls [19,20].”
MethodSelf-citationThe challenge of defining “ultra‐high‐risk” neuroblastoma
Morgenstern, D. A., Bagatell, R., Cohn, S. L., Hogarty, M. D., Maris, J. M., Moreno, L., Park, J. R., Pearson, A. D. J., Schleiermacher, G., Valteau‐Couanet, D., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27556 · Cited by 77
Self-citationZuccari, G., Milelli, A., Pastorino, F., Loi, M., Petretto, A., Parise, A., Marchetti, C., Minarini, A., Cilli, M., Emionite, L., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.286 · Cited by 68
Matthay, K. K., Weiss, B., Villablanca, J. G., Maris, J. M., Yanik, G. A., DuBois, S. G., Stubbs, J., Groshen, S., Tsao-Wei, D., Hawkins, R., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098624 · Cited by 67
“Nearly half of patients with neuroblastoma have metastatic disease at the time of presentation, with 40% survival (1,2).”
BackgroundSelf-citationMoroz, V., Machin, D., Hero, B., Ladenstein, R. L., Berthold, F., Kao, P., Yaa, O., Pearson, A. D. J., Cohn, S. L., & London, W. B. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28359 · Cited by 73
Self-citationChowdhury, F., Dunn, S. N., Mitchell, S. A., Mellows, T., Ashton‐Key, M., & Gray, J. C. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1029701 · Cited by 78
“Additionally, a number of tumor types such as high-risk neuroblastoma remain challenging to treat and still carry a poor prognosis.(4) In the case of high-risk neuroblastoma, treatment related mortality from current treatment regimens is substantial and there is little room to further intensify therapy.”
BackgroundNeuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Bagatell, R., Park, J. R., Acharya, S., Aldrink, J. H., Allison, J., Alva, E. D., Arndt, C., Benedetti, D. J., Brown, E. G., Cho, S. K., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0040 · Cited by 122
Self-citationThomas, S., Straathof, K. C. M., Himoudi, N., Anderson, J., & Pulè, M. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152196 · Cited by 69
“Indeed, antiGD2 monoclonal antibodies currently form part of standard treatment for high risk neuroblastoma, and their efficacy and toxicity profile is well-established [3,5].”
BackgroundNewman, E. A., & Nuchtern, J. G. (2016) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2016.09.007 · Cited by 73
Erbe, A. K., Wang, W., Carmichael, L. L., Kim, K., Mendonça, E. A., Song, Y., Hess, D., Reville, P. K., London, W. B., Naranjo, A. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1767 · Cited by 66
“Further advances are still needed for these high-risk patients; treatment with anti-GD2 immunotherapy is expensive andhas toxic side effects, andmany treated patients still relapse (2).”
BackgroundResultSelf-citationWu, H.-W., Sheard, M. A., Malvar, J., Fernández, G. E., DeClerck, Y. A., Blavier, L., Shimada, H., Theuer, C. P., Sposto, R., & Seeger, R. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3358 · Cited by 66
“18 has significantly improved event-free and overall survival of patients (1).”
BackgroundSelf-citationImmunotherapy of Childhood Sarcomas
Roberts, S. S., Chou, A. J., & Cheung, N.-K. V. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00181 · Cited by 65
“Given the success of anti-GD2 mAb therapy in neuroblastoma (21, 63) and the expression of GD2 by many sarcomas (64, 65), studies exploring the use of these mAbs in sarcomas, particularly in osteosarcoma, are underway.”
BackgroundMethodFlaadt, T., Ladenstein, R. L., Ebinger, M., Lode, H. N., Arnardóttir, H. B., Pöetschger, U., Schwinger, W., Meisel, R., Schuster, F. R., Döring, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01630 · Cited by 64
“47 41 (0) 31 (1) 29 (2) 26 (4) 24 (6) 20 (8) 17 (11) 15 (13) 7 (21) 4 (24) 18 14 (0) 11 (1) 8 (1) 8 (1) 5 (4) 4 (5) 2 (7) 2 (7) 1 (8) No BM infiltration BM infiltration”
InfluentialDi Paolo, D., Ambrogio, C., Pastorino, F., Brignole, C., Martinengo, C., Carosio, R., Loi, M., Pagnan, G., Emionite, L., Cilli, M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.142 · Cited by 62
Comparison of pain outcomes between two anti‐GD2 antibodies in patients with neuroblastoma
Anghelescu, D. L., Goldberg, J. L., Faughnan, L., Wu, J., Mao, S., Furman, W. L., Santana, V. M., & Navid, F. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25280 · Cited by 65
“18) anti-GD2 monoclonal antibody (mAb) combined with cytokines significantly improves clinical outcomes [3].”
BackgroundProton Radiotherapy for High-Risk Pediatric Neuroblastoma: Early Outcomes and Dose Comparison
Hattangadi, J. A., Rombi, B., Yock, T. I., Broussard, G., Friedmann, A. M., Huang, M., Chen, Y.-L. E., Lu, H., Kooy, H. M., & MacDonald, S. M. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.08.035 · Cited by 63
Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease
Harrison, D. J., & Schwartz, C. L. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0464-2 · Cited by 71
Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models
Crossland, D. L., Denning, W. L., Ang, S., Olivares, S., Mi, T., Switzer, K. C., Singh, H., Huls, H. M., Gold, K. S., Glisson, B. S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0187-2 · Cited by 68
Johnson, K. E., McGlynn, B., Saggio, J., Baniewicz, D., Zhuang, H., Maris, J. M., & Mossé, Y. P. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23062 · Cited by 62
“[3] reported 20% improvement in event-free survival (EFS) with the addition of immunotherapy to conventional treatment.”
BackgroundSelf-citationAdvances in the understanding of constitutional and somatic genomic alterations in neuroblastoma
Deyell, R. J., & Attiyeh, E. F. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.03.001 · Cited by 69
Neuroblastoma: A Tough Nut to Crack
Speleman, F., Park, J. R., & Henderson, T. O. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159169 · Cited by 68
Marachelian, A., Villablanca, J. G., Liu, C. W., Liu, B., Goodarzian, F., Lai, H., Shimada, H., Tran, H. C., Parra, J. A., Gallego, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2647 · Cited by 63
Self-citationRole and toxicity of radiation therapy in neuroblastoma patients: A literature review
Zhao, Q., Liu, Y., Zhang, Y., Meng, L., Wei, J., Wang, B., Wang, H., Xin, Y., Dong, L., & Jiang, X. M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102924 · Cited by 67
Lewis, E. C., Kraveka, J. M., Ferguson, W. S., Eslin, D. E., Brown, V. I., Bergendahl, G., Roberts, W. D., Wada, R. K., Oesterheld, J. E., Mitchell, D. S., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33044 · Cited by 62
Defining neuroblastoma: From origin to precision medicine
Sainero‐Alcolado, L., Bexelius, T. S., Santopolo, G., Yuan, Y., Liaño-Pons, J., & Arsenian‐Henriksson, M. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae152 · Cited by 68
Kushner, B. H., Ostrovnaya, I., Cheung, I. Y., Kuk, D., Kramer, K., Modak, S. I., Yataghene, K., & Cheung, N. V. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016704 · Cited by 65
“18 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) plus interleukin-2.(8) Nevertheless, relapse remains common and carries a dismal prognosis,(9-17) and has been deemed to be “invariably fatal” in a recent review.”
BackgroundTrial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 64
Immunotherapy Targets in Pediatric Cancer
Orentas, R. J., Lee, D. W., & Mackall, C. L. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00003 · Cited by 65
Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma
Ploessl, C., Pan, A., Maples, K. T., & Lowe, D. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016632013 · Cited by 72
“In the pivotal phase III trial (COG ANBL0032) that compared dinutuximab 17.5 mg/m2/day, GM-CSF, IL-2 (3 × 106 or 4.5 × 106 IU/m2/ day), and RA with standard therapy (RA), more than 90% of the 137 patients receiving dinutuximab experienced a treatment-related AE.12,26 Grade 3 or 4 toxicities that occurred more often in…”
BackgroundMethodInfluentialSpangler, J. B., Trotta, E., Tomala, J., Peck, A., Young, T. A., Savvides, C. S., Silveria, S. L., Votavová, P., Salafsky, J., Pande, V. S., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800578 · Cited by 63
The Role of Surgery in High-risk Neuroblastoma
Ryan, A. L., Akinkuotu, A. C., Pierro, A., Morgenstern, D. A., & Irwin, M. S. (2019) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001607 · Cited by 61
Liu, K. X., Naranjo, A., Zhang, F. F., DuBois, S. G., Braunstein, S. E., Voss, S. D., Khanna, G., London, W. B., Doski, J. J., Geiger, J. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03316 · Cited by 60
“After radiotherapy, all patients in ANBL0532 and A3973 received isotretinoin alone or were enrolled in the COG ANBL0032 or ANBL0931 trial, which included interleukin2, granulocyte-macrophage colony-stimulating factor, and dinutuximab, an antidisialoganglioside (GD2) chimeric antibody, in addition to isotretinoin.(18,1…”
MethodResultSelf-citationA scientometric analysis of neuroblastoma research
Martynov, I., Klima‐Frysch, J., & Schoenberger, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-06974-3 · Cited by 60
Langenberg, K. P. S., Looze, E. J., & Molenaar, J. J. (2021) · Cancers · doi:10.3390/cancers13174324 · Cited by 63
“Anti-GD2 therapy with dinutuximab increased the survival of patients with high-risk neuroblastoma and is implemented into frontline therapy [116].”
BackgroundDesai, A. V., Gilman, A. L., Ozkaynak, M. F., Naranjo, A. H., London, W. B., Tenney, S. C., Diccianni, M. B., Hank, J. A., Parisi, M. T., Shulkin, B. L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02478 · Cited by 80
“Disease evaluations were performed as described.(5) Response was assessed using the 1993 International Neuroblastoma Response Criteria.”
BackgroundMethodResultSelf-citationCosta, A., Thirant, C., Kramdi, A., Pierre‐Eugène, C., Louis‐Brennetot, C., Blanchard, O., Surdez, D., Gruel, N., Lapouble, E., Pierron, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004807 · Cited by 67
Lipidomics of Glycosphingolipids
Farwanah, H., & Kolter, T. (2012) · Metabolites · doi:10.3390/metabo2010134 · Cited by 67
“Neuropathic pain reactions in the immunotherapy were one of the major side-effects [161].”
BackgroundPeinemann, F., van Dalen, E. C., Enk, H., & Berthold, F. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010685.pub3 · Cited by 66
Globo-H Ceramide Shed from Cancer Cells Triggers Translin-Associated Factor X-Dependent Angiogenesis
Cheng, J., Wang, S., Lin, J., Tsai, Y.-C., Yu, J., Wu, J., Hung, J., Lin, J.-J., Wu, Y.-Y., Yeh, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1651 · Cited by 62
“shown to be effective targets for cancer immunotherapy (3).”
BackgroundSelf-citationAdvances in emerging drugs for the treatment of neuroblastoma
Berlanga, P., Cañete, A., & Castel, V. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1294159 · Cited by 66
“In a COG trial, anti-GD2 dinutuximab combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-2 showed improved 2-year EFS and OS when compared to 13-cis-retinoic acid alone [35].”
MethodTrial watch: Tumor-targeting monoclonal antibodies for oncological indications
Vacchelli, E., Pol, J. G., Bloy, N., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H. E. K., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985940 · Cited by 62
Koneru, B., Farooqi, A. S., Nguyen, T. H., Chen, W. H., Hindle, A., Eslinger, C. R., Makena, M. R., Burrow, T. A., Wilson, J., Smith, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd5750 · Cited by 66
Self-citationSiebert, N., Eger, C., Seidel, D., Jüttner, M., Zumpe, M., Wegner, D., Kietz, S., Ehlert, K., Veal, G. J., Siegmund, W., et al. (2016) · mAbs · doi:10.1080/19420862.2015.1130196 · Cited by 59
“18 (4£ 25 mg/m2/day, 8–20 h) in combination with cytokines resulted in increases of 20% and 11% in 2-year event-free and overall survival of high-risk NB patients, respectively.(4) In Europe, the International Society of Pediatric Oncology European Neuroblastoma Group (SIOPEN) commissioned a Good Manufacturing Practic…”
BackgroundMethodSiebert, N., Jensen, C., Troschke‐Meurer, S., Zumpe, M., Jüttner, M., Ehlert, K., Kietz, S., Müller, I., & Lode, H. N. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235108 · Cited by 59
AACR Cancer Progress Report 2015
Baselga, J., Bhardwaj, N., Cantley, L. C., DeMatteo, R., DuBois, R. N., Foti, M., Gapstur, S. M., Hahn, W. C., Helman, L. J., Jensen, R. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1846 · Cited by 55
“83)—to standard 13-cis-retinoic acid (RA) treatment significantly extended overall survival (143).”
BackgroundKroesen, M., Nierkens, S., Ansems, M., Wassink, M., Orentas, R. J., Boon, L., den Brok, M. H., Hoogerbrugge, P. M., & Adema, G. J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28463 · Cited by 64
“Most immunotherapeutic studies have been performed using C1300-derived cell lines in A/J mice for which only limited immunological tools are available due to the A/J genetic background.14–17 Additionally, C1300-derived cell lines, like Neuro-2a, do not express the tumor antigen GD2.”
BackgroundMethodInfluentialGlycosphingolipids are mediators of cancer plasticity through independent signaling pathways
Cumin, C., Huang, Y.-L., Rossdam, C., Ruoff, F., Céspedes, S. P., Liang, C.-Y., Lombardo, F. C., Coelho, R., Rimmer, N., Konantz, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111181 · Cited by 59
French, S., DuBois, S. G., Horn, B. N., Granger, M. P., Hawkins, R. A., Pass, A. K., Plummer, E. S., & Matthay, K. K. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24351 · Cited by 58
“18) and cytokines were recommended after response evaluation [6,23].”
BackgroundSelf-citationModak, S. I., Kushner, B. H., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26448 · Cited by 58
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
Mitwasi, N., Feldmann, A., Bergmann, R., Berndt, N., Arndt, C., Koristka, S., Kegler, A., Jureczek, J., Hoffmann, A., Ehninger, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21017 · Cited by 58
Jeong, G. H., Lee, K. H., Lee, I. R., Oh, J. H., Kim, D. W., Shin, J., Kronbichler, A., Eisenhut, M., van der Vliet, H. J., Abdel-Rahman, O. M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020143 · Cited by 58
The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma
Balis, F. M., Busch, C. M., Desai, A. V., Hibbitts, E., Naranjo, A. H., Bagatell, R., Irwin, M. S., & Fox, E. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28031 · Cited by 58
Management of Neuroblastoma: ICMR Consensus Document
Bansal, D., Totadri, S., Chinnaswamy, G., Agarwala, S., Vora, T. S., Arora, B., Prasad, M., Kapoor, G., Radhakrishnan, V. S., Siddharth, L., et al. (2017) · The Indian Journal of Pediatrics · doi:10.1007/s12098-017-2298-0 · Cited by 58
“18 with granulocyte–macrophage colony-stimulating factor (GM-CSF) and IL2 significantly improves outcome for high-risk NBL patients by acting on minimal residual disease [36, 37].”
BackgroundFetahu, I. S., Esser‐Skala, W., Dnyansagar, R., Sindelar, S., Rifatbegovic, F., Bileck, A., Skos, L., Bozsaky, E., Lazic, D., Shaw, L. E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39210-0 · Cited by 61
“These recent advancements in our understanding of the tumor microenvironment in primary NB have pavedtheway forthedevelopmentofanti-GD2immunotherapythat is currently administered along with the conventional treatment in high-risk NB 60 – 62 .”
Terme, M., Dorvillius, M., Cochonneau, D., Chaumette, T., Xiao, W., Diccianni, M. B., Barbet, J., Yu, A. L.-T., Paris, F., Sorkin, L. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087210 · Cited by 58
“event-free survival and overall survival in a phase III randomized clinical trial in children with high-risk neuroblastoma [3].”
BackgroundMethodInfluentialSelf-citationKushner, B. H., Kramer, K., Modak, S. I., & Cheung, N. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3317 · Cited by 59
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
Wagner, L. M., & Adams, V. R. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s124008 · Cited by 63
Barry, W. E., Jackson, J. R., Asuelime, G. E., Wu, H., Sun, J., Wan, Z., Malvar, J., Sheard, M. A., Wang, L. L., Seeger, R. C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1317 · Cited by 61
“Immunotherapy with anti-disialoganglioside (GD2) mAb (dinutuximab) could improve the efficacy of induction therapy since its use after myeloablative therapy, supported by autologous hematopoietic stem cell transplantation, has increased the 2-year EFS and overall survival (9).”
BackgroundSelf-citationBarone, G., Barry, A., Bautista, F. J., Brichard, B., Defachelles, A. S., Herd, F., Manzitti, C., Reinhardt, D., Rubio, P., Wieczorek, A., et al. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00469-9 · Cited by 56
Tumor-Associated Glycans and Immune Surveillance
Monzavi‐Karbassi, B., Pashov, A. D., & Kieber‐Emmons, T. (2013) · Vaccines · doi:10.3390/vaccines1020174 · Cited by 60
“surface antigen GD2 has resulted in lower recurrence rates and improved overall survival [116–119].”
BackgroundGenetic discoveries and treatment advances in neuroblastoma
Bagatell, R., & Cohn, S. L. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000296 · Cited by 60
Self-citationImmunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies
Shevtsov, M. A., & Multhoff, G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00492 · Cited by 57
GD2-targeting therapy: a comparative analysis of approaches and promising directions
Philippova, J., Shevchenko, J. A., & Sennikov, S. V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371345 · Cited by 59
“…survival with the combination of dinutuximab with GM-CSF, IL-2, and isotretinoin (ANBL0032) (87) compared to standard therapy with isotretinoin (88), prompting the FDA and EMA to approve this combination for maintenance therapy of high-risk neuroblastoma in pediatric patients after ASCT (89).”
BackgroundNot too little, not too much—just right! (Better ways to give high dose melphalan)
Shaw, P. J., Nath, C. E., & Lazarus, H. M. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.186 · Cited by 57
Therapeutic targets for neuroblastomas
Brodeur, G. M., Iyer, R., Courtland, J. L., Zhuang, T., Higashi, M., & Kolla, V. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.867946 · Cited by 59
“Further, a recent clinical trial showed a significant survival advantage of immunotherapy using an anti-GD2 antibody combined with granulocyte-macrophage colony-stimulating factor (GMCSF) or interleukin-2 in high-risk NB patients [117].”
Polishchuk, A. L., DuBois, S. G., Haas-Kogan, D. A., Hawkins, R. A., & Matthay, K. K. (2011) · Cancer · doi:10.1002/cncr.25987 · Cited by 55
Self-citationLode, H. N., Schmidt, M., Seidel, D., Huebener, N., Brackrock, D., Bleeke, M., Reker, D., Brandt, S. V., Mueller, H.-P., Helm, C. A., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1413-y · Cited by 54
Sung, K. W., Son, M. H., Lee, S. H., Yoo, K. H., Koo, H. H., Kim, J. Y., Cho, E. J., Lee, S. K., Choi, Y. S., Lim, D. H., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.86 · Cited by 54
Scursoni, A. M., Galluzzo, L., Camarero, S., Lopez, J. T., Lubieniecki, F. J., Sampor, C., Segatori, V. I., Gabri, M. R., Alonso, D. F., Chantada, G. L., et al. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/245181 · Cited by 59
“MRD, as reported by randomized studies [6].”
BackgroundMazloom, A., Louis, C. U., Nuchtern, J. G., Kim, E. S., Russell, H. V., Allen‐Rhoades, W. A., Krance, R. A., & Paulino, A. C. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.07.019 · Cited by 54
Membrane-bound TRAIL Supplements Natural Killer Cell Cytotoxicity Against Neuroblastoma Cells
Sheard, M. A., Asgharzadeh, S., Liu, Y., Lin, T.-Y., Wu, H.-W., Ji, L., Groshen, S. G., Lee, D. A., & Seeger, R. C. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829b4493 · Cited by 53
Self-citationTalleur, A. C., Triplett, B. M., Federico, S. M., Mamcarz, E. K., Janssen, W. E., Wu, J., Shook, D. R., Leung, W. H., & Furman, W. L. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.07.011 · Cited by 56
Cell death-based treatment of neuroblastoma
Valter, K., Zhivotovsky, B., & Gogvadze, V. G. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0060-1 · Cited by 59
Treatment and outcome of adult‐onset neuroblastoma
Suzuki, M., Kushner, B. H., Kramer, K., Basu, E. M., Roberts, S. S., Hammond, W. J., LaQuaglia, M. P., Wolden, S. L., Cheung, N. V., & Modak, S. I. (2018) · International Journal of Cancer · doi:10.1002/ijc.31399 · Cited by 53
New Agents, Emerging Late Effects, and the Development of Precision Survivorship
Chow, E. J., Antal, Z., Constine, L. S., Gardner, R. A., Wallace, W. H., Weil, B. R., Yeh, J. M., & Fox, E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4647 · Cited by 53
“combined with immunomodulatory (aldesleukin, sargramostim) and differentiating (isotretinoin) agents, have improved the 5-year overall survival of children with high-risk neuroblastoma from, 30% to approximately 50%.(15,16) However, acute toxicities are extensive, including capillary leak and neuropathic pain.”
BackgroundCavdarli, S., Dewald, J. H., Yamakawa, N., Guérardel, Y., Terme, M., Doussal, J. L., Delannoy, P., & Groux‐Degroote, S. (2019) · Glycoconjugate Journal · doi:10.1007/s10719-018-09856-w · Cited by 53
“As a consequence, disialogangliosides have been used as target molecules for cancer immunotherapy, such as GD2 in neuroblastoma [3].”
Development of smart anti-glycan reagents using immunized lampreys
McKitrick, T. R., Goth, C. K., Rosenberg, C. S., Nakahara, H., Heimburg‐Molinaro, J., McQuillan, A. M., Falco, R., Rivers, N. J., Herrin, B. R., Cooper, M. D., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0819-2 · Cited by 57
Gains, J. E., Moroz, V., Aldridge, M. D., Wan, S., Wheatley, K., Laidler, J., Peet, C., Bomanji, J. B., & Gaze, M. N. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04741-x · Cited by 56
Gauthier, M., Laroye, C., Bensoussan, D., Boura, C., & Decot, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103261 · Cited by 56
Epigenetic state determines inflammatory sensing in neuroblastoma
Wolpaw, A. J., Grossmann, L. D., Dessau, J. L., Dong, M. M., Aaron, B., Brafford, P. A., Volgina, D., Pascual‐Pasto, G., Rodríguez-García, A., Uzun, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102358119 · Cited by 55
Self-citationNeuroblastoma: an ongoing cold front for cancer immunotherapy
Kennedy, P. T., Zannoupa, D., Son, M. H., Dahal, L. N., & Woolley, J. F. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007798 · Cited by 55
“18 Furthermore, GD2 is expressed ubiquitously at high density in primary neuroblastomas regardless of disease stage, increasing its utility as an antigen for targeted immunotherapy.”
Management of Hepatoblastoma: ICMR Consensus Document
Agarwala, S., Gupta, A., Bansal, D., Vora, T. S., Prasad, M., Arora, B., Kapoor, G., Chinnaswamy, G., Radhakrishnan, V. S., Laskar, S. S., et al. (2017) · The Indian Journal of Pediatrics · doi:10.1007/s12098-017-2301-9 · Cited by 52
Novel Therapies for Relapsed and Refractory Neuroblastoma
Zage, P. E. (2018) · Children · doi:10.3390/children5110148 · Cited by 56
“18 (dinutuximab) as a component of maintenance therapy for children with high-risk neuroblastoma [121].”
BackgroundNivolumab and dinutuximab beta in two patients with refractory neuroblastoma
Ehlert, K., Hansjuergens, I., Zinke, A., Otto, S., Siebert, N., Henze, G., & Lode, H. N. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000540 · Cited by 52
Cheng, M. H., Ahmed, M., Xu, H., & Cheung, N. V. (2014) · International Journal of Cancer · doi:10.1002/ijc.29007 · Cited by 53
Edelman, M. J., Dvorkin, M. V., Laktionov, K., Navarro, A., Juan, Ó., Kozlov, V. V., Golden, G., Jordan, O., Deng, C., Bentsion, D., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.03.003 · Cited by 53
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma
Bagatell, R., DuBois, S. G., Naranjo, A. H., Belle, J., Goldsmith, K. C., Park, J. R., & Irwin, M. S. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30572 · Cited by 56
Valteau‐Couanet, D., Deley, M. L., Bergeron, C., Ducassou, S., Michon, J. M., Rubie, H., Teuff, G. L., Coze, C., Plantaz, D., Sirvent, N., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24713 · Cited by 53
“Administration of immunotherapy in addition to retinoic acid has recently been demonstrated to improve at least the 2-year EFS [19].”
BackgroundNatural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
Spel, L., Boelens, J. J., van der Steen, D. M., Blokland, N. J. G., van Noesel, M. M., Molenaar, J. J., Heemskerk, M. H. M., Boes, M. L., & Nierkens, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5657 · Cited by 51
“Antibody therapy in neuroblastoma initially yielded promising event-free survival benefits [6], however tumor relapse still occurred”
Daniotti, J. L., Lardone, R. D., & Vilcaes, A. A. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2015.00300 · Cited by 57
Gurunathan, S., & Kim, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122549 · Cited by 51
“including chemotherapy, surgery, and radiotherapy, immunotherapy with anti-disialoganglioside (GD2) antibody and differentiation therapy with 13-cis retinoic acid [5].”
BackgroundThe role of regulatory T cells in graft-versus-host disease management
Whangbo, J., Antin, J. H., & Koreth, J. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1709436 · Cited by 53
“Immune modulation with high-dose IL-2 (~2x10(6) IU/kg/day) led to durable remissions in patients with metastatic melanoma or renal cell carcinoma [85], and also has been effective in children for the treatment of neuroblastoma [86].”
BackgroundCurrent and coming challenges in the management of the survivorship population
Chow, E. J., Ness, K. K., Armstrong, G. T., Bhakta, N. H., Yeh, J. M., Bhatia, S., Landier, W., Constine, L. S., Hudson, M. M., & Nathan, P. C. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.02.007 · Cited by 55
Bobowski, M., Vincent, A., Steenackers, A., Colomb, F., SEUNINGEN, I. V., Julien, S., & Delannoy, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062559 · Cited by 50
“Complex gangliosides have also been used as target molecules for cancer immunotherapy, such as GD3 in melanoma [11,12] and GD2 in neuroblastoma [13,14].”
MethodMoreb, J. S., Uçar, D. A., & Khan, A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3213-5 · Cited by 55
“More recently, the addition of immunotherapy with anti-GD2 antibody dinutuximab plus cytokines to isotretinoin maintenance further improved event-free and overall survival rates [48].”
BackgroundLy, S., Anand, V., El-Dana, F., Nguyen, K., Cai, Y., Cai, S., Piwnica-Worms, H. M., Tripathy, D., Şahin, A. A., Andreeff, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001197 · Cited by 54
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.